CanSino Advances with Polio Vaccine Trials
Company Announcements

CanSino Advances with Polio Vaccine Trials

CanSino Biologics, Inc. Class H (HK:6185) has released an update.

CanSino Biologics Inc. has announced the approval of phase I/II clinical trials in Indonesia for its Recombinant Poliomyelitis Vaccine (CS-2036), a promising non-infectious candidate based on VLP technology. The vaccine, aligning with WHO’s future polio eradication goals, could potentially be integrated into combined vaccines. Investors are cautioned to trade carefully with the company’s shares amidst these developments.

For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskCanSino Biologics Sees Revenue Surge but Faces Net Losses
TipRanks HongKong Auto-Generated NewsdeskCanSino Biologics Advances Polio Vaccine with New Grant
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App